Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Authors
Keywords
Immune checkpoint inhibitors, PD-L1, PD-1, Multiple myeloma, Histone deacetylase, Bromodomain and extraterminal inhibitors, Oncolytic reovirus, MicroRNA
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1186/s13045-018-0589-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
- (2018) Bingxin Zheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1
- (2018) Bai He et al. BIOMEDICINE & PHARMACOTHERAPY
- Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells
- (2018) Sadamu Homma et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics
- (2017) Maria A. Smolle et al. FEBS Journal
- PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
- (2017) Tomas Jelinek et al. IMMUNOLOGY
- PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
- (2017) Sheema Almozyan et al. INTERNATIONAL JOURNAL OF CANCER
- The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
- (2017) Qingshui Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
- (2017) Daniel Yee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
- (2017) Frank (Xiaohu) Fan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
- (2017) Nasrin Rastgoo et al. Journal of Hematology & Oncology
- Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
- (2017) A Ray et al. LEUKEMIA
- Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
- (2017) K R Kelly et al. LEUKEMIA
- MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs
- (2017) A R Pyzer et al. LEUKEMIA
- Prognostic significance of PD-L1 in solid tumor
- (2017) Qianqian Wang et al. MEDICINE
- Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
- (2017) Carlos A. Morales-Betanzos et al. MOLECULAR & CELLULAR PROTEOMICS
- Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
- (2017) Christina M. Maher et al. MOLECULAR CANCER RESEARCH
- MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
- (2017) A Bouillez et al. ONCOGENE
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
- (2017) A Miller et al. Blood Cancer Journal
- Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
- (2017) Daniel E. Meyers et al. Blood Cancer Journal
- Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
- (2017) Pauline Gravelle et al. Oncotarget
- The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1
- (2017) Michele Cioffi et al. Oncotarget
- PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
- (2017) Valentina Audrito et al. Oncotarget
- Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
- (2017) Massimo Giuliani et al. Oncotarget
- Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
- (2017) Mayra Rachele Zarone et al. Scientific Reports
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
- (2017) Henrick Horita et al. NEOPLASIA
- Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
- (2016) G. An et al. BLOOD
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
- (2016) Jacalyn Rosenblatt et al. BLOOD
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer
- (2016) Jae Joon Han et al. Clinical Lung Cancer
- Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
- (2016) S.H. Lim et al. EUROPEAN JOURNAL OF CANCER
- Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)
- (2016) SABNA RAJEEV KRISHNAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
- (2016) Claudia Zelle-Rieser et al. Journal of Hematology & Oncology
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
- (2016) Andrew J Yee et al. LANCET ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
- (2016) A. Stiff et al. MOLECULAR CANCER THERAPEUTICS
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
- (2016) Zhong-Yi Dong et al. TUMOR BIOLOGY
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
- (2016) Ju Yeon Lee et al. Nature Communications
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
- (2016) M. Ishibashi et al. Cancer Immunology Research
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
- (2016) T. Jelinek et al. OncoImmunology
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy
- (2015) M. V. Dhodapkar et al. BLOOD
- Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
- (2015) Xi Wang et al. CELLULAR SIGNALLING
- A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
- (2015) B. Holkova et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Designing chimeric antigen receptors to effectively and safely target tumors
- (2015) Michael C Jensen et al. CURRENT OPINION IN IMMUNOLOGY
- ICSH guidelines for the standardization of bone marrow immunohistochemistry
- (2015) E. E. Torlakovic et al. International Journal of Laboratory Hematology
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
- (2015) H Suen et al. LEUKEMIA
- PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
- (2015) B Paiva et al. LEUKEMIA
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
- (2015) Yu Fujita et al. MOLECULAR THERAPY
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
- (2014) D. Massi et al. ANNALS OF ONCOLOGY
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
- (2014) Miguel F. Sanmamed et al. CANCER JOURNAL
- A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
- (2014) D. W. Sborov et al. CLINICAL CANCER RESEARCH
- Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy
- (2014) W.-S. Chang et al. JOURNAL OF IMMUNOLOGY
- In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma
- (2014) Maria Teresa Di Martino et al. PLoS One
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
- (2014) Eva Rossmann et al. Human Vaccines & Immunotherapeutics
- Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
- (2014) Immacolata Scognamiglio et al. Biomed Research International
- A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
- (2013) Weipeng Wang et al. HUMAN GENETICS
- Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
- (2013) T. J. Kearl et al. JOURNAL OF IMMUNOLOGY
- Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer
- (2013) XIAO SONG et al. ONCOLOGY REPORTS
- B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
- (2013) Sheng-Jia Shi et al. PLoS One
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- T-Cell Tolerance: Central and Peripheral
- (2012) Y. Xing et al. Cold Spring Harbor Perspectives in Biology
- Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
- (2011) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells
- (2009) V. V. Parekh et al. JOURNAL OF IMMUNOLOGY
- Cryptosporidium parvumInduces B7‐H1 Expression in Cholangiocytes by Down‐Regulating MicroRNA‐513
- (2009) Ai‐Yu Gong et al. JOURNAL OF INFECTIOUS DISEASES
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started